Latest database descriptions

• To assess the impact of low-to-moderate risk PCa on the subject’s QoL and
anxiety/depression at diagnosis and within the first year of treatment.
• To estimate health care consumption and utility values within the first year of
diagnosis of subjects with low-to-moderate risk PCa.
• To describe the profile and medical management of subjects with low-to-moderate
risk PCa from 5 countries in the European Union (EU), (France, Germany, Italy,
Spain and Sweden).

The main objective of this study is to evaluate the average duration of treatment via ARIXTRA® 2.5 mg at the hospital within the framework of the thromboprophylaxis indication

Describing the profile of patients with chronic ITP treated with TPO-R agonists and the clinical course of their disease over 2 years

To describe the population of adult patients with focal epilepsy currently being treated by an association of at least two antiepileptic medications, in terms of clinical profile, current medical management and seizure control, history of care, referral pathways and quality of life.